Abstract 2035P
Background
Multiple international guidelines suggest that pre-treatment cardiac markers should be taken prior to each cycle of treatment to support the early diagnosis and treatment of immune checkpoint inhibitor (ICI) induced myocarditis (1). As a large regional tertiary cancer centre with an established cardio-oncology service early adoption of baseline and subsequent cardiac surveillance has been implemented and its utility evaluated.
Methods
A retrospective analysis of patients whom had undergone baseline cardiac assessment prior to receiving ICI treatment at the Clatterbridge Cancer Centre between October 2022 and March 2023 was performed. Within the regional protocol all patients with abnormal cardiac markers (Pro-B Naturetic Peptide (Pro-BNP) >400 ng/L and or a high sensitivity troponin T (TropT) >14 ng/L) were subsequently monitored with pre-cycle cardiac biochemical monitoring for the first 3 cycles of ICI treatment.
Results
400 patients who commenced ICI treatment underwent baseline cardiac screening. Of these 169 patients (42.2%) had abnormal biomarkers: 36% (n=61) elevated TropT; 32% (n=54) elevated pro-BNP and 32% (n=54) had elevations in both. Within this cohort 3.3% (n=13) patients were diagnosed with ICI-induced myocarditis; 12 confirmed on cardiac MRI (cMRI) and 1 clinically diagnosed due to clinical instability. Of these 69% (n=9) patients had abnormal baselines and thus had pre-cycle monitoring; 4 did not. Of these 9; 8 were detected through symptoms alone; 1 patient was found to have elevated biomarkers but had already been clinically assessed prior to treatment and had been admitted prior to the biomarker results being reviewed.
Conclusions
Baseline cardiac assessment is useful, as the majority of patients that go on to develop ICI myocarditis have abnormal baseline values. However, the clinical utility of pre-cycle screening has not demonstrated enhanced or earlier detection of myocarditis compared to clinical assessment and represents an area of potential cost saving. Patients are either presenting mid-cycle or are identified via symptomatic review therefore investment is better placed in education and training to optimize clinical recognition and timely management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Dobson: Financial Interests, Personal, Invited Speaker: BMS, Roche. N. Garbutt: Financial Interests, Personal, Invited Speaker: BMS. T. Guinan: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche, Sanofi. A.C. Olsson-Brown: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche, Novartis, AZ, Eisai, B-I. All other authors have declared no conflicts of interest.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06